• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Associations with short-term and long-term use of inhaled corticosteroid in adults with asthma. A retrospective analysis.成人哮喘患者吸入性糖皮质激素短期和长期使用的相关性。一项回顾性分析。
Rev Assoc Med Bras (1992). 2025 Jul 7;71(6):e20241240. doi: 10.1590/1806-9282.20241240. eCollection 2025.
2
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma.长效毒蕈碱拮抗剂(LAMA)与吸入性糖皮质激素(ICS)联合使用,对比单独使用相同剂量ICS用于成人哮喘患者的疗效。
Cochrane Database Syst Rev. 2015 Aug 24;2015(8):CD011397. doi: 10.1002/14651858.CD011397.pub2.
3
Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma.对于患有持续性哮喘的成人和青少年,在吸入性糖皮质激素中添加抗白三烯药物。
Cochrane Database Syst Rev. 2017 Mar 16;3(3):CD010347. doi: 10.1002/14651858.CD010347.pub2.
4
Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults.间歇性吸入皮质类固醇疗法与安慰剂治疗儿童和成人持续性哮喘的比较。
Cochrane Database Syst Rev. 2015 Jul 22;2015(7):CD011032. doi: 10.1002/14651858.CD011032.pub2.
5
Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children.长效β2受体激动剂与吸入性糖皮质激素联合用于儿童慢性哮喘治疗。
Cochrane Database Syst Rev. 2015 Nov 24;2015(11):CD007949. doi: 10.1002/14651858.CD007949.pub2.
6
Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults.间歇性与每日吸入皮质类固醇治疗儿童和成人持续性哮喘的比较
Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD009611. doi: 10.1002/14651858.CD009611.pub3.
7
Corticosteroids for the treatment of Duchenne muscular dystrophy.用于治疗杜氏肌营养不良症的皮质类固醇
Cochrane Database Syst Rev. 2016 May 5;2016(5):CD003725. doi: 10.1002/14651858.CD003725.pub4.
8
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma.长效毒蕈碱拮抗剂(LAMA)与高剂量吸入性糖皮质激素(ICS)联合用于成人哮喘患者的疗效比较:LAMA联合ICS与高剂量ICS治疗成人哮喘的疗效对比
Cochrane Database Syst Rev. 2015 Jul 21;2015(7):CD011437. doi: 10.1002/14651858.CD011437.pub2.
9
Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events.慢性哮喘患者使用福莫特罗和吸入性类固醇进行常规治疗:严重不良事件
Cochrane Database Syst Rev. 2013 Jun 7(6):CD006924. doi: 10.1002/14651858.CD006924.pub3.
10
Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma.吸入长效β2受体激动剂与吸入性糖皮质激素联合使用与高剂量吸入性糖皮质激素治疗儿童和成人持续性哮喘的比较
Cochrane Database Syst Rev. 2005 Oct 19(4):CD005533. doi: 10.1002/14651858.CD005533.

本文引用的文献

1
Physical Activity and Sedentary Behavior as Treatable Traits for Clinical Control in Moderate-to-Severe Asthma.体力活动和久坐行为可作为中重度哮喘临床控制的可治疗特征。
J Allergy Clin Immunol Pract. 2024 Aug;12(8):2047-2055. doi: 10.1016/j.jaip.2024.03.012. Epub 2024 Mar 15.
2
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.贝那鲁肽治疗重度嗜酸性粒细胞性哮喘患者的每日维持吸入性皮质类固醇的降低(SHAMAL):一项随机、多中心、开放性、4 期研究。
Lancet. 2024 Jan 20;403(10423):271-281. doi: 10.1016/S0140-6736(23)02284-5. Epub 2023 Dec 7.
3
Treatable traits, combination inhaler therapy and the future of asthma management.可治疗的特征、联合吸入疗法和哮喘管理的未来。
Respirology. 2023 Sep;28(9):828-840. doi: 10.1111/resp.14556. Epub 2023 Jul 30.
4
Reliability and validity of the London Chest Activity of Daily Living scale for adults with asthma.伦敦哮喘患者日常生活活动量表的信度和效度。
J Asthma. 2024 Jan;61(1):1-9. doi: 10.1080/02770903.2023.2234990. Epub 2023 Jul 18.
5
The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review.ICS/福莫特罗缓解治疗方案在哮喘中的应用:综述。
J Allergy Clin Immunol Pract. 2023 Mar;11(3):762-772.e1. doi: 10.1016/j.jaip.2023.01.002. Epub 2023 Jan 10.
6
Criterion validity of ActiGraph monitoring devices for step counting and distance measurement in adults and older adults: a systematic review.计步和距离测量的 ActiGraph 监测设备在成年人和老年人中的标准效度:系统评价。
J Neuroeng Rehabil. 2022 Oct 17;19(1):112. doi: 10.1186/s12984-022-01085-5.
7
Dose-dependent association between inhaled corticosteroid use and risk of obesity and metabolic syndrome in asthma.吸入性皮质类固醇的使用与哮喘患者肥胖和代谢综合征风险的剂量相关性。
Allergy Asthma Proc. 2022 Sep 1;43(5):446-453. doi: 10.2500/aap.2022.43.220027.
8
Validity and reliability of the Glittre-ADL test in adults with asthma.哮喘成人的 Glittre-ADL 测试的有效性和可靠性。
Physiother Theory Pract. 2023 May;39(5):1052-1060. doi: 10.1080/09593985.2022.2114301. Epub 2022 Aug 27.
9
Does the use of inhaled corticosteroids in asthma benefit lung function in the long-term? A systematic review and meta-analysis.哮喘中吸入皮质类固醇的使用是否能长期有益于肺功能?系统评价和荟萃分析。
Eur Respir Rev. 2021 Jan 19;30(159). doi: 10.1183/16000617.0185-2020. Print 2021 Mar 31.
10
Functional tests for adults with asthma: validity, reliability, minimal detectable change, and feasibility.成人哮喘的功能测试:有效性、可靠性、最小可检测变化和可行性。
J Asthma. 2022 Jan;59(1):169-177. doi: 10.1080/02770903.2020.1838540. Epub 2020 Nov 6.

成人哮喘患者吸入性糖皮质激素短期和长期使用的相关性。一项回顾性分析。

Associations with short-term and long-term use of inhaled corticosteroid in adults with asthma. A retrospective analysis.

作者信息

Pedroso Ariele, Oliveira Joice Mara de, Alves Thainá Bessa, Puzzi Vitória Cavalheiro, Correia Natielly Soares, Ribeiro Heloisa Galdino Gumieiro, Ribeiro Marcos, Furlanetto Karina Couto

机构信息

Universidade Pitágoras Unopar Anhanguera, Research and Postgraduate Center - Londrina (PR), Brazil.

Universidade Estadual de Londrina, Laboratory of Research in Respiratory Physiotherapy - Londrina (PR), Brazil.

出版信息

Rev Assoc Med Bras (1992). 2025 Jul 7;71(6):e20241240. doi: 10.1590/1806-9282.20241240. eCollection 2025.

DOI:10.1590/1806-9282.20241240
PMID:40638457
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12245047/
Abstract

OBJECTIVE

The objective of this study was to compare anthropometric data and pulmonary and extrapulmonary physical functional outcomes of short- and long-term use of inhaled corticosteroids in adults with asthma.

METHODS

This cross-sectional study with retrospective analysis included clinically stable adults with asthma. Anthropometric data, exacerbation history, pulmonary function, disease control, dyspnea in daily life, quality of life, anxiety, depression, functional exercise capacity, performance in daily activities, body composition, physical activity level, respiratory muscle strength, lower limb strength, and handgrip strength were assessed and compared. Participants were separated into two groups based on the current duration of inhaled corticosteroids use below (short-term) or above (long-term) 3 years (≤3 years [n=37] and >3 years [n=30]) for comparative analysis.

RESULTS

A total of 67 participants were analyzed (69% female, 49±14 years, body mass index 29±6 kg/m², FEV1 2.21±0.79 L). The group ≤3 years presented statistically higher spirometric values and exercise capacity compared to the group >3 years even after analysis of covariance adjustments for age, body mass index, disease control, and treatment duration (forced vital capacity 3.39 [3.09-3.70] L vs. 2.93 [2.59-3.26] L, p=0.048; FEV1 2.40 [2.17-2.63] L vs. 2.00 [1.75-2.25] L, p=0.023; 6-min walk test 567 [536-599] vs. 519 [484-554] m, respectively, p=0.048). All the other variables were similar between groups (p>0.05 for all).

CONCLUSION

Participants who used inhaled corticosteroids for more than 3 years exhibited worse pulmonary function and exercise capacity. Despite this, exacerbation history, disease control, quality of life, anxiety, depression, and dyspnea in daily life, among other physical functional outcomes, were similar between short- and long-term use of inhaled corticosteroids in adults with asthma.

摘要

目的

本研究旨在比较哮喘成年患者短期和长期使用吸入性糖皮质激素后的人体测量数据、肺部及肺外身体功能结局。

方法

本横断面研究采用回顾性分析,纳入临床症状稳定的哮喘成年患者。评估并比较人体测量数据、加重病史、肺功能、疾病控制情况、日常生活中的呼吸困难、生活质量、焦虑、抑郁、功能运动能力、日常活动表现、身体成分、身体活动水平、呼吸肌力量、下肢力量和握力。根据目前吸入性糖皮质激素使用时长,将参与者分为两组,使用时长低于3年(短期)或高于3年(长期)(≤3年[n = 37]和> 3年[n = 30])进行对比分析。

结果

共分析了67名参与者(69%为女性,年龄49±14岁,体重指数29±6 kg/m²,第1秒用力呼气容积2.21±0.79 L)。即使在对年龄、体重指数、疾病控制情况和治疗时长进行协方差分析调整后,≤3年组的肺量计测量值和运动能力在统计学上仍高于> 3年组(用力肺活量3.39 [3.09 - 3.70] L对2.93 [2.59 - 3.26] L,p = 0.048;第1秒用力呼气容积2.40 [2.17 - 2.63] L对2.00 [1.75 - 2.25] L,p = 0.023;6分钟步行试验分别为567 [536 - 599]米对519 [484 - 554]米,p = 0.048)。两组间所有其他变量相似(所有p>0.05)。

结论

使用吸入性糖皮质激素超过3年的参与者肺功能和运动能力较差。尽管如此,在哮喘成年患者中,短期和长期使用吸入性糖皮质激素后的加重病史、疾病控制情况、生活质量、焦虑、抑郁以及日常生活中的呼吸困难等其他身体功能结局相似。